Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. - Archive ouverte HAL Access content directly
Journal Articles BMC Pharmacology and Toxicology Year : 2013

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.

(1, 2) , (3) , (4) , (4) , (4) , (1) , (4) , (4) , (4) , (1, 5) , (4)
1
2
3
4
5

Abstract

BACKGROUND: Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes. METHODS: Anakinra was given subcutaneously at doses between 2 and 10 mg/kg (maximum 100 mg) per day. Anakinra concentrations were recorded in patients, as well as C-reactive protein (CRP) levels, on different occasions. The data were fitted to a pharmacokinetic-pharmacodynamic model via a population approach using Monolix. RESULTS: A total of 87 children and adolescents, 8 months to 21 years old, were available for pharmacokinetic evaluation. A one compartment model with linear absorption and elimination described the pharmacokinetics. Taking into account bodyweight to explain variations in apparent clearance (CL/F) and distribution volume (V/F) significantly reduced the associated between-subject and between-occasion variabilities. The final estimates were 6.24 L/h/70 kg and 65.2 L/70 kg for CL/F and V/F respectively. A mixture pharmacodynamic model described the CRP level change during anakinra treatment for the SJIA patients with 2 subpopulations, patients with high baseline and large CRP decrease and patients with low baseline and small CRP decrease followed by a re-increase in CRP levels. There was no significant effect of the combined anti-inflammatory treatment. The proportion of patients for which the development of a resistance to treatment was significant was 62% and the corresponding time was approximately 60 days CONCLUSIONS: Based on effects in SJIA, a prospective dosage adjustment was proposed based on a 0.4 mg/L Css target in order to obtain a CRP decrease to 10 mg/L or below.
Fichier principal
Vignette du fichier
2050-6511-14-40.pdf (205.84 Ko) Télécharger le fichier
Vignette du fichier
2050-6511-14-40.xml (44.25 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00850983 , version 1 (10-08-2013)

Identifiers

Cite

Saik Urien, Christophe Bardin, Brigitte Bader-Meunier, Richard Mouy, Sandrine Compeyrot-Lacassagne, et al.. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.. BMC Pharmacology and Toxicology, 2013, 14 (1), pp.40. ⟨10.1186/2050-6511-14-40⟩. ⟨inserm-00850983⟩

Collections

INSERM UNIV-PARIS
142 View
411 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More